AZ Q2 Preview: Pipeline, COVID-19 and M&A Key Focus

Oncology Drugs Will Be Growth Drivers

24 Jul 2020

• By Sten Stovall

AstraZeneca’s half-year results, out on 30 July, will be keenly watched due to the pharma’s attractive near-term growth, pipeline catalysts and its promising COVID-19 vaccine.

AZ’s pipeline is emerging as one of the strongest in the pharma sector • Source: Shutterstock

AstraZeneca PLC’s recent and coming launches of new drugs and its expanding pipeline, along with a big presence in China and the promising vaccine that is being developed against SARS-CoV-2 virus in partnership with Oxford University, should ensure keen investor interest when the UK-based drugmaker reports second quarter and half-year results on 30 July.

The company has returned to financial growth on the back of a rejuvenated pipeline and new drug offerings that are...